Lunasin has been shown to suppress signaling through the FAK/ERK/NF-κB pathway in colon cancer cells [31] and Akt/NF-κB signaling in macrophages during activation of lipopolysaccharide-induced inflammation [29, 33]. Here, NFKB1 is linked to colonic neoplasm.